The FDA has approved sotatercept-csrk, the first activin signaling inhibitor therapy, for the management of patients with pulmonary arterial hypertension (PAH). Based on the Phase 3 STELLAR trial,...
Following a multicenter clinical trial, a new treatment for pneumonia caused by Acinetobacter baumannii-calcoaceticus has been approved for use in adults.
Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.
Following a multicenter study, the FDA approved the combination of albuterol and budesonide—an inhaled corticosteroid—for the treatment of asthma in adults.
It is a new indication for the medication, which had already been FDA-approved for the treatment of patients with complicated UTIs and complicated intraabdominal infections who have limited or no...
Previously to this drug’s approval, there were no treatment options for adults with interstitial lung disease associated with systemic sclerosis or scleroderma.
The American Thoracic Society says the FDA approved the asthma treatment with lack of consideration for patient safety and for a public policy process.
The FDA has approved the first treatment option in the United States for patients age 3 years or older with congenital or idiopathic pulmonary arterial hypertension.
